Trial · NCT01059448
Adverse events92
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 92
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Placebo / AMG 827 210 mg Q2WK | 0 | 49 | |
| other | Vertigo | Ear and labyrinth disorders | 70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 1 | 55 | |
| other | Vertigo | Ear and labyrinth disorders | 140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK | 1 | 53 | |
| other | Vertigo | Ear and labyrinth disorders | 210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 3 | 54 | |
| other | Conjunctivitis | Eye disorders | Placebo / AMG 827 210 mg Q2WK | 0 | 49 | |
| other | Conjunctivitis | Eye disorders | 70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 3 | 55 | |
| other | Conjunctivitis | Eye disorders | 140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK | 0 | 53 | |
| other | Conjunctivitis | Eye disorders | 210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 1 | 54 | |
| other | Gastritis | Gastrointestinal disorders | Placebo / AMG 827 210 mg Q2WK | 0 | 49 | |
| other | Gastritis | Gastrointestinal disorders | 70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 4 | 55 | |
| other | Gastritis | Gastrointestinal disorders | 140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK | 1 | 53 | |
| other | Gastritis | Gastrointestinal disorders | 210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 0 | 54 | |
| other | Nausea | Gastrointestinal disorders | Placebo / AMG 827 210 mg Q2WK | 1 | 49 | |
| other | Nausea | Gastrointestinal disorders | 70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 1 | 55 | |
| other | Nausea | Gastrointestinal disorders | 140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK | 0 | 53 | |
| other | Nausea | Gastrointestinal disorders | 210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 3 | 54 | |
| other | Injection site pain | General disorders | Placebo / AMG 827 210 mg Q2WK | 5 | 49 | |
| other | Injection site pain | General disorders | 70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 1 | 55 | |
| other | Injection site pain | General disorders | 140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK | 2 | 53 | |
| other | Injection site pain | General disorders | 210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK | 3 | 54 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01059448/events